SCHEMBL5505490

SCHEMBL5505490

CCOC(=O)c1cnc2ccccc2c1NCCCCCNC(=O)OCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.65
MEN1 O00255 1/20 0.65
PKM P14618 1/20 0.65
MAPT P10636 7/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
TP53 P04637 2/20 0.58
NPSR1 Q6W5P4 2/20 0.57
ALDH1A1 P00352 4/20 0.55
KDM4E B2RXH2 3/20 0.55
LMNA P02545 2/20 0.55
HPGD P15428 2/20 0.55
TDP1 Q9NUW8 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.53
MAPK1 P28482 2/20 0.50
RXFP1 Q9HBX9 1/20 0.50
THRB P10828 1/20 0.49
POLB P06746 1/20 0.49
RAD52 P43351 1/20 0.49
UHRF1 Q96T88 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5501450 0.88 KMT2A (0.76) KMT2AMEN1PKMMAPTSMN1; SMN2
SCHEMBL2045638 0.84 KMT2A (0.79) KMT2AMEN1PKMMAPTSMN1; SMN2
SCHEMBL5501524 0.83 KMT2A (0.74) KMT2AMEN1PKMMAPTSMN1; SMN2
SCHEMBL5315591 0.83 KMT2A (0.77) KMT2AMEN1PKMMAPTSMN1; SMN2
SCHEMBL5500673 0.82 KMT2A (0.72) KMT2AMEN1PKMMAPTSMN1; SMN2
SCHEMBL5506586 0.82 KMT2A (0.76) KMT2AMEN1PKMMAPTSMN1; SMN2
SCHEMBL5505918 0.81 KMT2A (0.77) KMT2AMEN1PKMMAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL11242122 0.80 MAPT (0.75) KMT2AMEN1PKMMAPTSMN1; SMN2
SCHEMBL530155 0.79 KMT2A (0.78) KMT2AMEN1PKMMAPTSMN1; SMN2
SCHEMBL5501700 0.76 TOP2A (0.46) KMT2AMEN1PKMMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1753724-A1 HETEROCYCLIC DERIVATIVES FOR TREATMENT OF HYPERLIPIDEMIA AND RELATED DISEASES AVANIR PHARMACEUTICALS (US) 2007-02-21 EP disclosed
US-20060009487-A1 Heterocyclic derivatives for treatment of hyperlipidemia and related diseases SIRCAR JAGADISH C 2006-01-12 US disclosed
WO-2005123686-A1 HETEROCYCLIC DERIVATIVES FOR TREATMENT OF HYPERLIPIDEMIA AND RELATED DISEASES AVANIR PHARMACEUTICALS (US) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009487-A1 Heterocyclic derivatives for treatment of hyperlipidemia and related diseases LDLR, NPC1L1, CETP KMT2A 3106/4885MEN1 4136/4885PKM 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.